Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neovascular (Wet) Age-related Macular Degeneration”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT02988895
What this trial is testing

Episcleral Brachytherapy for the Treatment of Wet AMD

Who this might be right for
Macular Degeneration, Choroidal Neovascularization
Salutaris Medical Devices, Inc. 11
Large-scale testing (Phase 3)UnknownNCT04667039
What this trial is testing

Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis®

Who this might be right for
Age Related Macular Degeneration (ARMD)
AO GENERIUM 408
Large-scale testing (Phase 3)Not Yet RecruitingNCT07520318
What this trial is testing

This is a 96-week, Multicenter Study in Patients With Neovascular AMD That Evaluates OCUL101 for Efficacy, Safety, Durability, and Pharmacokinetics, Comparing it With Another Treatment. The Study Will be Conducted in Two Parts, Part A and Part B.

Who this might be right for
Adults With Neovascular Age-related Macular Degeneration
Shenzhen Oculgen Biomedical Technology Co., Ltd. 255
Testing effectiveness (Phase 2)Study completedNCT01134055
What this trial is testing

Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration

Who this might be right for
Macular Degeneration
GlaxoSmithKline 510
Large-scale testing (Phase 3)Study completedNCT02243878
What this trial is testing

Stereotactic Radiotherapy for Wet AMD (STAR)

Who this might be right for
Neovascular (Wet) Age-related Macular Degeneration (AMD)
King's College Hospital NHS Trust 411
Not applicableStudy completedNCT05324150
What this trial is testing

M Charts Versus Amsler Test in Evaluating Metamorphopsia in nAMD

Who this might be right for
Macular Degeneration, WetMetamorphopsia
Ospedale Santa Croce-Carle Cuneo 57
Post-approval studies (Phase 4)Study completedNCT04774926
What this trial is testing

Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 122
Post-approval studies (Phase 4)Ended earlyNCT05473715
What this trial is testing

Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment

Who this might be right for
Neovascular (Wet) Age-related Macular Degeneration
Bayer 3
Testing effectiveness (Phase 2)Study completedNCT01535950
What this trial is testing

Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)

Who this might be right for
Neovascular Age-elated Macular Degeneration (Wet AMD)Exudative Macular Degeneration
Novartis Pharmaceuticals 43
Not applicableStudy completedNCT05131646
What this trial is testing

Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study

Who this might be right for
Neovascular Age-related Macular Degeneration
Clearside Biomedical, Inc. 15
Not applicableStudy completedNCT00656903
What this trial is testing

High Speed Indocyanine Green Angiography Findings in Ranibizumab Treatment for Wet Age-related Macular Degeneration

Who this might be right for
Macular Degeneration
National Eye Institute (NEI) 75
Large-scale testing (Phase 3)Study completedNCT04005352
What this trial is testing

Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

Who this might be right for
Age-related Macular Degeneration
Novartis Pharmaceuticals 734
Testing effectiveness (Phase 2)Enrolling By InvitationNCT05210803
What this trial is testing

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)
AbbVie 116
Early research (Phase 1)WithdrawnNCT00538538
What this trial is testing

Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD)

Who this might be right for
Retinal HemorrhageMacular Degeneration
Corewell Health East
Early research (Phase 1)Active Not RecruitingNCT06817343
What this trial is testing

A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)Neovascular (Wet) Age-related Macular Degeneration (AMD)
Exegenesis Bio 12
Post-approval studies (Phase 4)Study completedNCT02161575
What this trial is testing

Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 103
Testing effectiveness (Phase 2)Looking for participantsNCT07776522
What this trial is testing

Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration

Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
West China Hospital 50
Large-scale testing (Phase 3)Study completedNCT00509795
What this trial is testing

Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)

Who this might be right for
Macular Degeneration
Regeneron Pharmaceuticals 1,217
Testing effectiveness (Phase 2)Active Not RecruitingNCT06550011
What this trial is testing

Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)

Who this might be right for
Neovascular (Wet) AMD
Avirmax Biopharma Inc 18
Not applicableEnded earlyNCT05038371
What this trial is testing

Connective Tissue Growth Factor in Patients With Neovascular Age Related Macular Degeneration

Who this might be right for
Wet Macular Degeneration
Johns Hopkins University 20
Next Page